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Abstract There are differences in the kinetic properties of the
liver and brain microsomal glucose-6-phosphate transport
systems suggesting the possibility of tissue specific isoforms.
The availability of a human liver cDNA sequence which is
mutated in patients with deficiencies of liver microsomal glucose-
6-phosphate transport (glycogen storage disease 1b) made it
possible to determine if a brain isoform exists. Northern blots of
liver and brain RNA revealed that the mRNA of the brain form is
slightly longer than the liver one. Isolation and sequencing of the
respective human brain cDNA revealed that the brain protein has
an additional 22 amino acid sequence.
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1. Introduction
Liver glucose-6-phosphatase (EC 3.1.3.9) plays a key role in
blood glucose homeostasis, catalysing the terminal step of
both gluconeogenesis and glycogenolysis [1,2]. The principal
sites of expression of the enzyme are liver and kidney [3], but
it also present in a variety of other human tissues such as
brain, pancreas, the adrenal foetal zone and intestinal mucosa
[4^8]. The glucose-6-phosphatase enzyme is the catalytic sub-
unit of a multi-protein system situated with its active site in-
side in the endoplasmic reticulum membrane of the cells [2,8].
This system (Fig. 1) also involves at least three di¡erent trans-
port functions termed T1 (glucose-6-phosphate), T2 (phos-
phate) and T3 (glucose) [2]. The carriers allow the transport
of substrate molecules through the membrane into the endo-
plasmic reticulum lumen and then the elimination of the re-
action products from the endoplasmic reticulum cisternae
(Fig. 1) (for a review see [2]). The genetic de¢ciencies of the
catalytic subunit, T1, T2, and T3 are termed glycogen storage
disease 1a, 1b, 1c and 1d respectively [8]. These are severe
metabolic disorders that usually present with fasting hypo-
glycaemia [8]. Glycogen storage disease 1b is often more prob-
lematical than the other subtypes as the patients have addi-
tional symptoms e.g. neutropenia [8].
In liver the glucose-6-phosphate transport protein is the
rate limiting step in glucose-6-phosphate hydrolysis in intact
microsomal vesicles [9] and the KM for glucose-6-phosphatase
activity with glucose-6-phosphate as substrate in normal in-
tact microsomes isolated from a variety of species is usually
less than 5 mM e.g. [10^12]. It was therefore rather surprising
that the KM reported in intact microsomes with glucose-6-
phosphate as substrate in brain was much higher, s 20 mM
[13]. This di¡erence in KM raised the possibility that the glu-
cose-6-phosphate transport proteins in brain and liver might
be di¡erent.
A liver EST (expressed sequence tag) with some sequence
homology to bacterial sugar phosphoester transporters was
recently found to be mutated in patients with defective micro-
somal glucose-6-phosphate transport (glycogen storage dis-
ease 1b) [14]. We have used the published human liver se-
quence as a probe to show that the brain and liver mRNA
are di¡erent sizes and also to clone the human brain isoform.
2. Materials and methods
2.1. Materials
The M-MLV reverse transcriptase and pGEM-T cloning kit were
both from Promega; Taq polymerase/Pwo mix was from Hybaid.
Radioactive compounds were from Amersham.
2.2. Human and animal tissues
Adult human biopsy tissue and rat tissues were rapidly frozen in
liquid nitrogen and stored at 380‡C prior to use. Adult Wistar rats
were either allowed free access to food and water, or were denied food
but not water for 48 h. Diabetes was induced by a single tail vein
injection of 75 mg/kg body weight streptozotocin in citrate bu¡er pH
4.5 [15]. Only animals in which the development of diabetes was con-
¢rmed 48 h later by blood glucose measurements s 12 mM were used.
Ethical approval was given by the Tayside Health Board Ethical
Committee.
2.3. RNA preparations
The RNA was isolated according to the TRIZOL procedure (Gib-
co). The amounts of RNA were estimated by the spectrophotometric
method at 260 nm.
2.4. Northern blot
Total RNA (5 to 20 Wg, see ¢gure legends) was separated on a 1.3%
formaldehyde-agarose gel, transferred to GeneScreen membranes
(Dupont-NEN) and ¢xed with UV. The membranes were rehydrated
in 5USSC, prehybridised for 4 h at 42‡C in 1 M NaCl, 50% forma-
mide, 1% SDS, 10% dextran sulphate, 10 mg/ml sheared denatured
herring sperm DNA and hybridised overnight with a [32P]-labelled
probe (full length human liver cDNA mutated in glycogen storage
disease 1b) in the same bu¡er. The blot was washed twice for 30
min at 65‡C in 2USSC, 1% SDS, twice for 30 min at 65‡C in
1USSC, 1% SDS and twice for 30 min at 65‡C in 0.2USSC, 1%
sodium dodecyl sulphate. The membranes were then exposed over-
night to X-ray ¢lm (GRI) at 380‡C.
2.5. RT-PCR
One Wg of total RNA was reverse transcribed at 42‡C for 50 min in
a volume of 25 Wl with 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM
MgCl2, 10 mM DTT, 800 WM dNTPs, 2^4 U RNasin ribonuclease
inhibitor, 0.5 Wg oligodT primer and 100 U M-MLV reverse tran-
scriptase, RNase H minus. The enzyme was inactivated at 94‡C for
5 min. Ten Wl of the cDNA was then combined with 50 mM KCl, 10
mM Tris-HCl, pH 9.0, 0.1% Triton X-100, 200 WM dNTPs, 1.5 mM
MgCl2, 25 pmoles sense (5PCCATGGCAGCCCAGGGCTATG3P)
and antisense (5PCTTCACTCAGCGTTGTTGGACACTCGGCC-
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C3P) primers and 2.5 U of a mixture of Taq/Pwo polymerases. PCR
was carried out as follows using a Perkin-Elmer Cetus thermo-cycler:
cycle 1: 94‡C (5 min), 65‡C (2 min), 72‡C (3 min), cycles 2^29: 94‡C
(1 min), 65‡C (2 min), 72‡C (3 min) and last cycle: 94‡C (1 min), 65‡C
(2 min), 72‡C (10 min). PCR products were analysed on a 1% agarose
gel containing ethidium bromide.
2.6. DNA sequencing
PCR products were puri¢ed from low melting point agarose using
Wizard PCR preps kit (Promega) then incubated with 10 mM dATP
and 2.5 U Taq polymerase (MBI Fermentas) at 72‡C for 1 h. The
DNA was re-puri¢ed and cloned into pGEM-T vector. DNA sequen-
ces were determined both manually from double stranded plasmids by
the dideoxynucleotide-chain termination method using the T7 Sequen-
ase version 2.0 sequencing kit from Amersham and automatically on
an applied Biosystems automated DNA sequencer.
3. Results and discussion
The di¡erent characteristics of the microsomal glucose-6-
phosphate in liver and brain suggested the possibility that
di¡erent isoforms of T1 might exist [10,13]. The existence of
a liver EST, exhibiting sequence similarities with a family of
bacterial proteins involved in phosphoester transport [16] to-
gether with the ¢nding that the EST was mutated in patients
su¡ering from liver endoplasmic reticulum glucose-6-phos-
phate transport defects (glycogen storage disease 1b) [14],
made it feasible to investigate whether or not a brain isoform
exists. The EST was most like UhpC, a membrane protein
involved in the regulation of UhpT (the sugar phosphate car-
rier of Escherichia coli) [16]; UhpT is itself very similar to
UhpC (32% strict homology or 58% similarity) [16]. We do
not yet know if, like in bacteria, the mammalian endoplasmic
reticulum glucose-6-phosphate transport system is comprised
of more than one protein. However for simplicity, in this
paper we have termed both the published EST liver cDNA
and the protein G6PT1, because in patients this protein is
essential for glucose-6-phosphate transport ([14] and Marco-
longo et al., submitted for publication).
3.1. A comparison of the mRNAs in liver and brain
Northern blots of RNA prepared from fed, starved and
diabetic rat liver and brain tissue were visualised using as a
probe the human liver cDNA that is mutated in glycogen
storage disease 1b (Fig. 2). The size of the mRNA visualised
was larger in brain than in liver strongly suggesting that tissue
speci¢c isoforms exist. The amount of the mRNA in liver is
increased as expected in the starved and diabetic liver (Fig. 2)
where it is well known that the glucose-6-phosphatase system
is upregulated in these conditions e.g. [9,10,15]. In contrast, in
brain no signi¢cant change in levels was observed between the
di¡erent metabolic states, which may indicate di¡erential reg-
ulation of the two isoforms. Previously tissue speci¢c di¡er-
ences in the regulation of the glucose-6-phosphatase catalytic
subunit have been demonstrated and this presumably re£ects
the di¡erent roles of the glucose-6-phosphatase system in the
individual tissues [2^4].
3.2. Cloning and sequencing of the T1 translocase in liver and
brain
RT-PCR was performed with human brain and liver RNA
using speci¢c oligonucleotides designed against the liver se-
quence. Two di¡erently sized products were obtained, the liv-
er PCR product had the expected size with regard to oligo
binding position (1.3 kbp) whereas the brain one was slightly
larger (not shown). The sequences of both products were iden-
tical except that the brain sequence contained an extra 66 bp
(Fig. 3). This extra sequence does not interrupt the reading
frame and 22 additional amino acids are then included in the
protein sequence (Figs. 3 and 4). The human liver cDNA
encodes a protein of 429 amino acids [14] and the brain iso-
form has 451 amino acids (Fig. 4).
There is evidence for the existence of two di¡erent endo-
plasmic reticulum Pi transport proteins with di¡erent charac-
teristics [12,17]. These have been termed T2K and T2L or
G6PT2K and G6PT2L. To be consistent we therefore suggest
that the G6PT1 isoforms be termed K and L respectively in the
order in which they have been described.
The two di¡erent forms of human G6PT1 are strictly ho-
mologous except for the extra 22 amino acids in G6PT1L
indicating that G6PT1K and G6PT1L are products of a single
gene. Recently, the gene for glycogen storage disease 1b has
been mapped to chromosome 11q23 by linkage analysis in
nine a¡ected families [18]. The isoforms are due to a di¡er-
ential splicing of a single 9 exon gene on chromosome 11 and
G6PT1K, the liver type mRNA does not contain the 66 bp
exon 7 (Marcolongo et al., submitted for publication).
The bacterial phosphoester transporter UhpT has been pre-
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Fig. 1. Schematic representation of the microsomal glucose-6-phos-
phatase system. Glucose-6-phosphate is transported in the endoplas-
mic reticulum by a glucose-6-phosphate transport system (G6PT1)
and dephosphorylated by the glucose-6-phosphatase catalytic subu-
nit (G6PC). The phosphate and glucose produced are leaving the
endoplasmic reticulum lumen via the phosphate and glucose trans-
port systems (G6PT2 and G6PT3 respectively). The term system is
used for each function to denote that normal function of each may
require more than one polypeptide chain.
Fig. 2. Northern blot of rat liver and brain RNA from fed (F),
starved (S) or diabetic (D) animals. The three ¢rst lanes were loaded
with 5 Wg total RNA from rat liver. The three other lanes were
loaded with 20 Wg total RNA from rat brain. The hybridisation was
carried out using the full length human liver cDNA that is mutated
in glycogen storage disease 1b as a [32P]-labelled probe.
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dicted to have 12 membrane spanning regions [19]. Alignment
of G6PT1K with UhpT also led to the suggestion of 12 mem-
brane spanning regions [14]. The C terminal KK motif of
membrane spanning endoplasmic reticulum proteins is an en-
doplasmic reticulum retention signal [20,21], which is on the
cytoplasmic side of the endoplasmic reticulum membrane.
Adding this information to the predicted topology produces
a model (Fig. 5) showing that the extra 22 amino acids are in
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Fig. 4. Sequence alignment of the human liver (G6PT1K) and brain (G6PT1L) forms of the protein mutated in glycogen storage disease 1b.
The extra 22 amino acid sequence found in brain is underlined. All the other residues are strictly conserved between the two forms of the pro-
tein.
Fig. 3. Sequence of the human brain cDNA (G6PT1L) encoding the brain isoform of the protein mutated in glycogen storage disease 1b and
deduced amino acid sequence.
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a loop region. Until the topology of G6PT1 is unequivocally
established it will not be certain which side of the endoplasmic
reticulum is the loop containing the extra amino acids resides.
In bacteria the UhpT transporter and a second protein regu-
latory protein termed UhpC are both involved in phosphoes-
ter transport. We do not yet know if mammalian endoplasmic
reticulum glucose-6-phosphate transport also requires a sec-
ond protein for normal functioning in vivo as no mammalian
equivalent of the UhpC regulatory protein has been cloned. It
is interesting that the 22 extra amino acids described here in
G6PT1L have similarity to a region of UhpC between amino
acids 387^410 (48% similarity and 31% strict homology)
which suggests that they may have the potential to provide
part of the regulatory function supplied by UhpC in bacteria.
The existence of a further exon of 66 bp in brain G6PT1L
has implications for glycogen storage disease 1b as it seems
possible that there will be patients with mutations in that exon
where liver glucose-6-phosphate transport would not be af-
fected.
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Fig. 5. Schematic model of the G6PT1 protein transmembrane
structure predicted in comparison to those made on the homologous
bacterial UhpC protein [19]. The loop containing extra 22 amino
acids of G6PT1L is shown in bold.
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